Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

× No keyword cloud information.

49 in total

1. Humoral immunity to gram-negative bacillary infections in experimental animals and man.

Authors: W R McCabe
Journal: Infection Date: 1975 Impact factor: 3.553

2. Opsonizing antibodies, host factors, and the limulus assay for endotoxin.

Authors: L S Young
Journal: Infect Immun Date: 1975-07 Impact factor: 3.441

3. A murine monoclonal antibody specific for the outer core oligosaccharide of Salmonella lipopolysaccharide.

Authors: R S Tsang; K H Chan; P Y Chau; K C Wan; M H Ng; S Schlecht
Journal: Infect Immun Date: 1987-01 Impact factor: 3.441

4. [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors: E T Rietschel; H Brade
Journal: Infection Date: 1987 Mar-Apr Impact factor: 3.553

5. Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria.

Authors: M Trautmann; H Hahn
Journal: Infection Date: 1985 May-Jun Impact factor: 3.553

6. Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.

Authors: K A Joiner; M A Schmetz; M E Sanders; T G Murray; C H Hammer; R Dourmashkin; M M Frank
Journal: Proc Natl Acad Sci U S A Date: 1985-07 Impact factor: 11.205

7. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Authors: M I Marks; E J Ziegler; H Douglas; L B Corbeil; A I Braude
Journal: J Clin Invest Date: 1982-04 Impact factor: 14.808

Review 8. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors: A Cometta; J D Baumgartner; M P Glauser
Journal: Clin Exp Immunol Date: 1994-07 Impact factor: 4.330

9. Human antiserum for prevention of the local shwartzman reaction and death from bacterial lipopolysaccharides.

Authors: E J Ziegler; H Douglas; A I Braude
Journal: J Clin Invest Date: 1973-12 Impact factor: 14.808

10. Lipid A and anti-lipid A.

Authors: I Mattsby-Baltzer; B Kaijser
Journal: Infect Immun Date: 1979-03 Impact factor: 3.441